Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

NatK Harnessing natural killer cells to combat chemotherapy resistance

Coordinator
University of Bristol, United Kingdom
Runs
1 May 2026 to 30 April 2028
Status
Running
EU funding
€276k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101208111

What the project is doing

In the project's own words, from its summary on CORDIS.

Chemotherapy resistance remains a major challenge in cancer treatment, often leading to poor patient outcomes. NatK aims to (1) identify predictive signature of chemoresistance and (2) develop innovative therapeutic strategies to overcome it, using triple negative breast cancer (TNBC) as a model. The focus is on natural killer (NK) cells, hypothesising that reactivating these cells could enhance their cytotoxicity against chemoresistant tumours.

State-of-the-art 10X Visium spatial transcriptomics will be employed to analyse primary TNBC samples from chemotherapy responders and non-responders, mapping NK cell infiltration and activity within the tumour microenvironment (TME). Advanced bioinformatics will identify immune-related signatures of chemoresistance, validated in independent patient cohorts to develop a robust NK cell-related biomarker for patient stratification.

To translate these findings into therapeutic strategies, specific genes upregulated in chemoresistant tumours will be targeted to enhance NK cell-mediated cytotoxicity. Co-culture systems with NK cells and patient-derived organoids will be used to evaluate the impact of gene modulation, followed by the development of small molecule inhibitors targeting promising candidates. The efficacy of combining NK cell activation with chemotherapy will then be assessed both in vitro and in vivo, aiming to establish a novel combination therapy to combat chemoresistance.

NatK integrates state-of-the-art spatial transcriptomics, functional immune profiling and patient-derived organoid models to elucidate chemoresistance mechanisms. The insights gained may have broader implications, potentially extending to other cancer types and guiding targeted immunotherapy development. In line with the MSCA Postdoctoral Fellowship objectives, this interdisciplinary research will advance expertise in cutting-edge biomedical technologies, foster international collaboration, and contribute to advancing oncology in Europe.

Topics

Who is involved

OrganisationCityCountryRole
University of BristolBristolUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI